Tier 1 — highest

Magnesium citrate supplementation decreased blood pressure and HbA1c in normomagnesemic subjects with metabolic syndrome: a 12-week, placebo-controlled, double-blinded pilot trial

Kseniia Afitska, Julia Clavel, Klaus Kisters, Jürgen Vormann, Tanja Werner
Magnesium research 2021 34(3):130-139

Bibliography

PubMed
PMID 34859788
Funding
Funding is not specified in the indexed abstract or accessible funding metadata. Consult the original publication for the declaration.
Competing interests
A competing-interest declaration is not available in the indexed abstract or accessible disclosure metadata.

Study snapshot

DesignRandomized controlled clinical trial
ModelHuman participants
Sample24 participants with metabolic syndrome and normal serum magnesium
Intervention400 mg/day elemental magnesium as citrate or placebo
Duration12 weeks
EndpointsBlood pressure; HbA1c; Vitamin D and magnesium status

What the study showed, in plain terms

This publication examines blood pressure, hba1c, vitamin d and magnesium status. Study population or evidence base: 24 participants with metabolic syndrome and normal serum magnesium. Intervention or exposure: 400 mg/day elemental magnesium as citrate or placebo.

Key findings

The pilot reported improvements in blood pressure and HbA1c with magnesium citrate. Vitamin D concentrations also increased within the magnesium group.

What this study can and cannot tell us

Very small pilot trial with multiple outcomes. Larger studies are needed before extrapolating the magnitude of its results.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research